{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:52:12Z","timestamp":1789692732593,"version":"4.0.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The AmBisome Therapy Induction Optimization (AMBITION-cm) trial, conducted in eastern and southern Africa, showed that a single, high dose (10 mg\/kg) of liposomal amphotericin B, given with an oral backbone of fluconazole and flucytosine, was noninferior to the World Health Organization (WHO)\u2013recommended regimen of 7 days of amphotericin B deoxycholate plus flucytosine for treatment of human immunodeficiency virus (HIV)\u2013associated cryptococcal meningitis and has been incorporated into WHO treatment guidelines. We believe that the trial also has important implications for the treatment of HIV-associated cryptococcal meningitis in high-income settings. We advance the arguments, supported by evidence where available, that the AMBITION-cm trial regimen is likely to be as fungicidal as the currently recommended 14-day liposomal amphotericin\u2013based treatments, better tolerated with fewer adverse effects, and confer significant economic and practical benefits and, therefore, should be included as a treatment option in guidance for HIV-associated cryptococcal treatment in high-income settings.<\/jats:p>","DOI":"10.1093\/cid\/ciac792","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T17:08:22Z","timestamp":1664298502000},"page":"944-949","source":"Crossref","is-referenced-by-count":13,"title":["How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus\u2013Associated Cryptococcal Meningitis to High-Income Settings?"],"prefix":"10.1093","volume":"76","author":[{"given":"Thomas S","family":"Harrison","sequence":"first","affiliation":[{"name":"Institute of Infection and Immunity, St George's University London , London , United Kingdom"},{"name":"Clinical Academic Group in Infection and Immunity, St George's University Hospitals NHS Foundation Trust , London , United Kingdom"},{"name":"Medical Research Council Centre for Medical Mycology, University of Exeter , Exeter , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine , London , United Kingdom"},{"name":"Botswana Harvard AIDS Institute Partnership , Gaborone , Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry C","family":"Mwandumba","sequence":"additional","affiliation":[{"name":"Clinical Sciences Department, Liverpool School of Tropical Medicine , Liverpool , United Kingdom"},{"name":"Malawi-Liverpool-Wellcome Clinical Research Programme , Blantyre , Malawi"},{"name":"Department of Medicine, Kamuzu University of Health Sciences , Blantyre , Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Boulware","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University , Kampala , Uganda"},{"name":"Division of Infectious Diseases and International Medicine, University of Minnesota , Minneapolis, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina C","family":"Hosseinipour","sequence":"additional","affiliation":[{"name":"Lilongwe Medical Relief Trust (University of North Carolina Project) , Lilongwe , Malawi"},{"name":"Department of Medicine, University of North Carolina , Chapel Hill, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lortholary","sequence":"additional","affiliation":[{"name":"Institut Pasteur, National Center for Scientific Research, Molecular Mycology Unit and National Reference Center for Invasive Mycoses and Antifungals, Unit\u00e9s Mixtes de Recherche 2000 , Paris , France"},{"name":"Universit\u00e9 de Paris-Cit\u00e9, Necker Pasteur Center for Infectious Diseases and Tropical Medicine, H\u00f4pital Necker Enfants Malades, Assistance Publique\u2013H\u00f4pitaux de Paris, IHU Imagine , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Meintjes","sequence":"additional","affiliation":[{"name":"Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine , Cape Town , South Africa"},{"name":"Department of Medicine, University of Cape Town , Cape Town , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mosepele","family":"Mosepele","sequence":"additional","affiliation":[{"name":"Botswana Harvard AIDS Institute Partnership , Gaborone , Botswana"},{"name":"Department of Internal Medicine, University of Botswana , Gaborone , Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1459-5554","authenticated-orcid":false,"given":"Joseph N","family":"Jarvis","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine , London , United Kingdom"},{"name":"Botswana Harvard AIDS Institute Partnership , Gaborone , Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis","volume":"17","author":"Rajasingham","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/cid\/cix430","article-title":"Advanced human immunodeficiency virus disease in Botswana following successful antiretroviral therapy rollout: incidence of and temporal trends in cryptococcal meningitis","volume":"65","author":"Tenforde","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"e0009376","DOI":"10.1371\/journal.pntd.0009376","article-title":"Equity in clinical trials for HIV-associated cryptococcal meningitis: a systematic review of global representation and inclusion of patients and researchers","volume":"15","author":"Lawrence","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/QAI.0000000000002095","article-title":"Mortality after cryptococcal infection in the modern antiretroviral therapy era","volume":"82","author":"Hevey","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa2111904","article-title":"Single-dose liposomal amphotericin B treatment for cryptococcal meningitis","volume":"386","author":"Jarvis","year":"2022","journal-title":"N Engl J Med"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM199707033370103","article-title":"Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group","volume":"337","author":"van der Horst","year":"1997","journal-title":"N Engl J Med"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"e67311","DOI":"10.1371\/journal.pone.0067311","article-title":"A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi","volume":"8","author":"Rothe","year":"2013","journal-title":"PLoS One"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1086\/593194","article-title":"Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda","volume":"47","author":"Longley","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1086\/649861","article-title":"Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi","volume":"50","author":"Nussbaum","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/QAD.0b013e328354b419","article-title":"A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis","volume":"26","author":"Jackson","year":"2012","journal-title":"AIDS"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1710922","article-title":"Antifungal combinations for treatment of cryptococcal meningitis in Africa","volume":"378","author":"Molloy","year":"2018","journal-title":"N Engl J Med"},{"key":"2023030705143123100_","author":"World Health Organization"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S1473-3099(22)00234-1","article-title":"Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme","volume":"22","author":"Mashau","year":"2022;","journal-title":"Lancet Infect Dis"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single-dose liposomal amphotericin B for visceral leishmaniasis in India","volume":"362","author":"Sundar","year":"2010","journal-title":"N Engl J Med"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"e00090","DOI":"10.1128\/AAC.00090-17","article-title":"Experimental models of short courses of liposomal amphotericin B for induction therapy for cryptococcal meningitis","volume":"61","author":"Lestner","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/ciy515","article-title":"Short-course high-dose liposomal amphotericin B for human immunodeficiency virus-associated cryptococcal meningitis: a phase 2 randomized controlled trial","volume":"68","author":"Jarvis","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/cid\/ciaa016","article-title":"Cerebrospinal fluid early fungicidal activity as a surrogate endpoint for cryptococcal meningitis survival in clinical trials","volume":"71","author":"Pullen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/604716","article-title":"Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients","volume":"49","author":"Bicanic","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1128\/AAC.42.3.528","article-title":"Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis","volume":"42","author":"Diamond","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(04)16301-0","article-title":"Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial","volume":"363","author":"Brouwer","year":"2004","journal-title":"Lancet"},{"key":"2023030705143123100_","author":"World Health Organization"},{"key":"2023030705143123100_","author":"Gilead"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2011.00944_1.x","article-title":"British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011","volume":"12","author":"Nelson","year":"2011","journal-title":"HIV Med"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/hiv.12878","article-title":"2019 Update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0","volume":"21","author":"Ryom","year":"2020","journal-title":"HIV Med"},{"key":"2023030705143123100_"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1086\/653606","article-title":"Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety","volume":"51","author":"Hamill","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1086\/588792","article-title":"High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial","volume":"47","author":"Bicanic","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2023030705143123100_"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"e60431","DOI":"10.1371\/journal.pone.0060431","article-title":"Predictors of mortality and differences in clinical features among patients with cryptococcosis according to immune status","volume":"8","author":"Brizendine","year":"2013","journal-title":"PLoS One"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1097\/01.aids.0000252060.80704.68","article-title":"Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy","volume":"20","author":"Lortholary","year":"2006","journal-title":"AIDS (London, England)"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/cid\/cix867","article-title":"Comparative epidemiology and outcomes of human immunodeficiency virus (HIV), non-HIV non-transplant, and solid organ transplant associated cryptococcosis: a population-based study","volume":"66","author":"George","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1086\/515074","article-title":"Early mycological treatment failure in AIDS-associated cryptococcal meningitis","volume":"28","author":"Robinson","year":"1999","journal-title":"Clin Infect Dis"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/hiv.12387","article-title":"Prognostic implications of baseline anaemia and changes in haemoglobin concentrations with amphotericin B therapy for cryptococcal meningitis","volume":"18","author":"Tugume","year":"2017","journal-title":"HIV Med"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3201\/eid2004.131277","article-title":"Nosocomial drug-resistant bacteremia in 2 cohorts with cryptococcal meningitis, Africa","volume":"20","author":"Rajasingham","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"e1845","DOI":"10.1016\/S2214-109X(22)00450-8","article-title":"Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial","volume":"10","author":"Lawrence","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"e56269","DOI":"10.1371\/journal.pone.0056269","article-title":"Epidemiology of cryptococcal meningitis in the US: 1997\u20132009","volume":"8","author":"Pyrgos","year":"2013","journal-title":"PLoS One"},{"key":"2023030705143123100_","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/cid\/cis725","article-title":"Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4 &lt;100 cells\/mcL","volume":"55","author":"Rajasingham","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2023030705143123100_","article-title":"The acceptability of the AMBITION-cm treatment regimen for HIV-associated cryptococcal meningitis: findings from a qualitative methods study of participants and researchers in Botswana and Uganda","author":"Lawrence","year":"","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac792\/48585628\/ciac792.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/5\/944\/49424672\/ciac792.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/5\/944\/49424672\/ciac792.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T18:56:09Z","timestamp":1701111369000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/5\/944\/6724283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,9,27]]},"published-print":{"date-parts":[[2023,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac792","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,9,27]]}}}